Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

31.28 +0.11 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Royalty Pharma Reports Second Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
2 Dividend Stocks Wall Street Thinks Can Rise by 50%
These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit. 
Via The Motley Fool
Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Third Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
$10M Bet On GameStop? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Earnings Outlook For Royalty Pharma
Via Benzinga
Preview: Royalty Pharma's Earnings
Via Benzinga
$122M Bet On Occidental Petroleum? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed mixed on Wednesday, there were a few notable insider trades. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 32 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 64 companies achieved new lows for the year. 
Via Benzinga
Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 129 stocks made new 52-week lows. 
Via Benzinga
$12.5M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
Royalty Pharma Reports First Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Present At The BofA Securities 2023 Health Care Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Second Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce First Quarter 2023 Financial Results on May 9, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces $1.0 Billion Share Repurchase Program
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and PureTech Health Enter Into KarXT Royalty Agreement for Up to $500 Million
From Royalty Pharma plc
Via GlobeNewswire
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
From PureTech Health plc
Via Business Wire
Royalty Pharma Raises Full Year 2023 Guidance
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday, 79 stocks hit new 52-week lows. 
Via Benzinga
Insiders Selling TransMedics Group And 2 Other Stocks
The Nasdaq 100 closed higher by around 0.7% on Monday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Top 5 Health Care Stocks That May Rocket Higher In Q1 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Royalty Pharma Reports Q4 and Full Year 2022 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS